Allergy Therapeutics PLC Issue of Equity (3752C)
April 13 2017 - 2:00AM
UK Regulatory
TIDMAGY
RNS Number : 3752C
Allergy Therapeutics PLC
13 April 2017
Allergy Therapeutics plc
("Allergy Therapeutics" or the "Group")
Issue of equity in respect of the exercise of warrants and
options
13 April 2017 Allergy Therapeutics (AIM:AGY), the fully
integrated specialty pharmaceutical group specialising in allergy
vaccines, announces the issue and allotment of a total number of
673,748 new ordinary shares of 0.1p each in the capital of the
Company ("Ordinary Shares") pursuant to the exercise of 353,748
share warrants issued to JSB Partners, LP in 2012 and pursuant to
the exercise of 320,000 share options by certain employees.
Application has been made to the London Stock Exchange for
admission to trading of the new Ordinary Shares on AIM
("Admission"). It is expected that Admission will take place and
that dealings in the new Ordinary Shares on AIM will commence at
8.00 a.m. on 18 April 2017. The new Ordinary Shares will, when
issued, be credited as fully paid and will rank pari passu in all
respects with the existing Ordinary Shares in the capital of the
Company, including the right to receive all dividends or other
distributions made, paid or declared in respect of such shares
after the date of issue of the new Ordinary Shares.
Allergy Therapeutics' enlarged issued ordinary share capital
immediately following Admission will be 594,117,768 Ordinary Shares
with voting rights attached. The Company has no Ordinary Shares in
Treasury; therefore the total number of voting rights in Allergy
Therapeutics is 594,117,768. This figure may be used by
shareholders as the denominator for the calculations by which they
will determine whether they are required to notify an interest in,
or a change to their interest in, the share capital of the Company
under the FCA's Disclosure and Transparency Rules.
- ENDS -
For further information, please contact:
Allergy Therapeutics
+44 (0) 1903 845 820
Manuel Llobet, Chief Executive Officer
Nick Wykeman, Finance Director
Panmure Gordon
+44 (0) 20 7886 2500
Freddy Crossley / Duncan Monteith, Corporate Finance
Tom Salvesen, Corporate Broking
Consilium Strategic Communications
+44 20 3709 5700
Mary-Jane Elliott / Ivar Milligan
allergytherapeutics@consilium-comms.com
Note to editors:
About Allergy Therapeutics
Allergy Therapeutics is an international specialty
pharmaceutical group focussed on the treatment and diagnosis of
allergic disorders including immunotherapy vaccines that cure
disease. The Group sells proprietary products and third party
products from its subsidiaries in nine major European countries and
via distribution agreements in an additional ten countries.
Formed in 1999 out of Smith Kline Beecham, Allergy Therapeutics
is headquartered in Worthing, UK with MHRA-approved manufacturing
facilities. The Group employs c.495 employees and is listed on the
London Stock Exchange (AIM:AGY). For more information, please see
www.allergytherapeutics.com.
This information is provided by RNS
The company news service from the London Stock Exchange
END
IOEELLFFDZFZBBF
(END) Dow Jones Newswires
April 13, 2017 02:00 ET (06:00 GMT)
Allergy Therapeutics (LSE:AGY)
Historical Stock Chart
From Mar 2024 to Apr 2024
Allergy Therapeutics (LSE:AGY)
Historical Stock Chart
From Apr 2023 to Apr 2024